---
title: "BioNTech initiates the first Phase III clinical trial of B7-H3 ADC, expected to obtain results in January 2031"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/273812231.md"
description: "BioNTech has initiated the first Phase III clinical trial of DB-1311/BNT324, expected to recruit 736 participants, with results to be announced in January 2031. BNT324 is a B7-H3 ADC developed by DUALITYBIO, which was licensed to BioNTech in April 2023, granting the latter development, production, and commercialization rights outside of China"
datetime: "2026-01-27T08:23:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/273812231.md)
  - [en](https://longbridge.com/en/news/273812231.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/273812231.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/273812231.md) | [繁體中文](https://longbridge.com/zh-HK/news/273812231.md)


# BioNTech initiates the first Phase III clinical trial of B7-H3 ADC, expected to obtain results in January 2031

The U.S. ClinicalTrials.gov website shows that BioNTech has launched the first Phase III clinical trial of DB-1311/BNT324, expected to recruit 736 participants, with results anticipated in January 2031.

BNT324 is a B7-H3 ADC developed by DUALITYBIO (09606.HK), which was licensed to BioNTech in April 2023. The company holds the rights for the development, production, and commercialization of the drug outside of China

### Related Stocks

- [BioNTech SE (BNTX.US)](https://longbridge.com/en/quote/BNTX.US.md)
- [ARK Genomic Revolution ETF (ARKG.US)](https://longbridge.com/en/quote/ARKG.US.md)
- [iShares US Pharmaceuticals ETF (IHE.US)](https://longbridge.com/en/quote/IHE.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/en/quote/IBB.US.md)
- [First Trust NYSE Arca Biotech ETF (FBT.US)](https://longbridge.com/en/quote/FBT.US.md)
- [Invesco Nasdaq Biotechnology ETF (IBBQ.US)](https://longbridge.com/en/quote/IBBQ.US.md)
- [DUALITYBIO-B (09606.HK)](https://longbridge.com/en/quote/09606.HK.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/en/quote/BBH.US.md)
- [ALPS Medical Breakthroughs ETF (SBIO.US)](https://longbridge.com/en/quote/SBIO.US.md)
- [Sutro Biopharma, Inc. (STRO.US)](https://longbridge.com/en/quote/STRO.US.md)
- [State Street®HlthCrSelSectSPDR®ETF (XLV.US)](https://longbridge.com/en/quote/XLV.US.md)
- [Vanguard Health Care ETF (VHT.US)](https://longbridge.com/en/quote/VHT.US.md)
- [Direxion Daily S&P Biotech Bear 3X ETF (LABD.US)](https://longbridge.com/en/quote/LABD.US.md)
- [ProShares Ultra Nasdaq Biotechnology (BIB.US)](https://longbridge.com/en/quote/BIB.US.md)
- [State Street® SPDR® S&P® Biotech ETF (XBI.US)](https://longbridge.com/en/quote/XBI.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/en/quote/PBE.US.md)
- [iShares Global Healthcare ETF (IXJ.US)](https://longbridge.com/en/quote/IXJ.US.md)

## Related News & Research

- [BioNTech Co-Founders to Launch Independent mRNA Venture as Company Refocuses on Late-Stage Pipeline](https://longbridge.com/en/news/278540977.md)
- [Galecto Rebrands as Damora Therapeutics with New Ticker](https://longbridge.com/en/news/278556054.md)
- [Deutsche Bank  Keeps Their Buy Rating on BioNTech SE (BNTX)](https://longbridge.com/en/news/278570303.md)
- [CSP International Publishes Disclosure on V2D Création Acquisition](https://longbridge.com/en/news/278778570.md)
- [Pfizer Inc. Reports Positive Phase 2 Results for tilrekimig (PF-07275315) in Atopic Dermatitis](https://longbridge.com/en/news/278448836.md)